established from the peripheral blood of a 36-year-old woman with plasma cell leukemia (IgG) in 1977

Cell Type:
B cell
Tissue Origin:
Research Area:
Cancer Research/Cell Biology
Immunotherapy / Hematology
Cell Characteristics:

Transfection Information

Lonza Optimized Protocol
Optimization Guideline
The table below shows data for the cell type and Nucleofector™ Platform selected. Those data are either based on Lonza Optimized Protocols or on results shared from customers who performed an optimization based on our guidelines. In case no data are shown for the selected Nucleofector™ Platform, please take a look at our optimization strategy to get further guidance on how to easily determine optimal Nucleofection conditions yourself.
Protocol Kit Program Cells Efficiency Viable Cells Substrate Format Platform
SF DN-100 1e6 58% 65% Plasmid (general) 400 ng 4D X-Unit
SF EH-100 1e6 51% 59% Plasmid (general) 400 ng 4D X-Unit
SF EO-100 1e6 47% 70% Plasmid (general) 400 ng 4D X-Unit
SF EN-138 1e6 54% 53% Plasmid (general) 400 ng 4D X-Unit